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Abstract
The HIV-1 capsid is involved in all infectious steps from reverse transcription to integration site selection, and is the target of
multiple host cell and pharmacologic ligands. However, structural studies have been limited to capsid monomers (CA), and
the mechanistic basis for how these ligands influence infection is not well understood. Here we show that a multi-subunit
interface formed exclusively within CA hexamers mediates binding to linear epitopes within cellular cofactors NUP153 and
CPSF6, and is competed for by the antiretroviral compounds PF74 and BI-2. Each ligand is anchored via a shared
phenylalanine-glycine (FG) motif to a pocket within the N-terminal domain of one monomer, and all but BI-2 also make
essential interactions across the N-terminal domain: C-terminal domain (NTD:CTD) interface to a second monomer.
Dissociation of hexamer into CA monomers prevents high affinity interaction with CPSF6 and PF74, and abolishes binding to
NUP153. The second interface is conformationally dynamic, but binding of NUP153 or CPSF6 peptides is accommodated by
only one conformation. NUP153 and CPSF6 have overlapping binding sites, but each makes unique CA interactions that,
when mutated selectively, perturb cofactor dependency. These results reveal that multiple ligands share an overlapping
interface in HIV-1 capsid that is lost upon viral disassembly.
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Introduction
The early events in HIV-1 infection proceed through a complex
series of steps that include translocation of the viral core through
the cytosol, reverse transcription, capsid uncoating, nuclear entry
and integration. A number of host cofactors have been identified
that regulate these processes, including cyclophilin A (CypA [1]),
the karyopherin substrate CPSF6 [2,3], nuclear import/pore
proteins TNPO3, NUP153, NUP358 [4,5,6], and LEDGF [7].
Inhibition of CypA with cyclosporine reduces viral infectivity [8],
promotes innate immune sensing [3] and alters the site of viral
integration [9]. Depletion of TNPO3 [10,11], NUP358 or NUP153
inhibits nuclear entry and infectivity and, at least in the case of
TNPO3 and NUP358, alters integration site targeting [11,12].
Finally, CPSF6 depletion inhibits infection of primary macrophages
by revealing HIV-1 to innate immune sensing [3].
How the virus coordinates recruitment of these cofactors and
how they influence each other is not well understood, but there is a
growing body of data suggesting that the viral capsid plays a key
role. Viral dependence on post-entry cofactors is dictated by CA
whilst CA mutations affect all post-entry processes from reverse
transcription to integration site selection [9,10,13,14,15]. CypA
and NUP358 bind directly to an exposed loop in the CA NTD
[16,17] and loop mutations such as G89A or P90A that impair
CA:CypA interactions phenocopy CypA deletion [18]. HIV-1
utilization of TNPO3 and NUP153 is also CA-dependent, and
viruses with CA mutations such as N57A, Q63A/Q67A, K70R
and N74D are insensitive to depletion of these proteins [19,20].
These residues all define a recently identified protein-protein
interface on CA that binds CPSF6, suggesting that CPSF6 may act
upstream of other nuclear import cofactors and determine their
usage [21]. However, CPSF6 binding to CA is critically dependent
upon an ‘FG’ motif [21] and NUP153 has recently been shown to
interact directly with viral cores using a similar motif [20].
While CPSF6 and NUP153 share a common ‘FG’ binding
motif, their interactions with CA are distinct. For example, CA
mutant N74D abolishes binding to CPSF6 [21] but not NUP153
[20]. Moreover, despite this different binding pattern, N74D
escapes both CPSF6 and NUP153 dependence suggesting that
CPSF6 and NUP153 have distinct roles. A role for NUP153 in
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HIV-1 nuclear entry is substantiated by depletion experiments in
which the production of 2-LTR circles, which form only within the
nucleus, and HIV-1 integration, are reduced [22]. CPSF6 may
also have a role in nuclear import by recruiting TNPO3 to the
virus and providing transport to active nuclear pores [23]. In
support of this, it has been shown that TNPO3 is not required for
infection when CPSF6 binding is abolished by the CA mutation
N74D [2]. Further evidence for a link between CPSF6 and TNPO3
include data showing that mutants of TNPO3 that are selectively
impaired for interaction with CPSF6 do not support HIV-1 infec-
tion [24], whilst TNPO3-depleted cells are refractory to wild-type
HIV-1 infection only in the presence of endogenous CPSF6 [25].
Finally, the addition of a nuclear export sequence (NES) onto
CPSF6 inhibited HIV-1 in TZM-bl cells [25]. However, the role of
CPSF6 and Nup153 is complicated by the fact that perturbing their
involvement gives rise to different phenotypes in different cell types.
For instance, mutants T54A/N57A and Q63A/Q67A (which are
sensitive to the synthetic restriction factor TRIM-CPSF6 but not
TRIM-NUP153 [20]) have reduced infection in nondividing HeLa
cells but only T54A/N57A has reduced infectivity in nondividing
macrophages [26]. Meanwhile, neither depletion of CPSF6 [2] nor
introduction of CPSF6 non-binding CA mutations N74D or T107A
[19,21] reduces infection of HIV-1 in single round replication assays
in cell lines, whilst in macrophages N74D or CPSF6 depletion
inhibits replication [3]. Importantly, it is not only changes in infec-
tion that are associated with an impaired ability of the capsid to
engage CPSF6; N74D results in altered integration site targeting in
HeLa cells [9].
The antiviral compounds PF-3450074 (PF74) [27] and BI-2
[28] have been shown to interact with the same pocket in the CA
NTD as NUP153 and CPSF6. PF74 inhibits infection, blocks
reverse transcription [29] and prevents replication in macrophages
[3]. BI-2 has the same reported affinity for CA as PF74 yet does
not block reverse transcription nor is as potent an inhibitor. These
differences in reverse transcription inhibition are mirrored by
NUP153 and CPSF6; NUP153 does not block reverse transcription
but expression of a CPSF6 mutant lacking its nuclear localization
sequence (hereafter referred to as ‘CPSF6DNLS’) inhibits viral DNA
synthesis [3,30]. While complexed crystal structures exist for the
four ligands - NUP153, CPSF6, PF74 and BI-1 (a BI-2 precursor) -
these structures provide no mechanistic basis to explain their differ-
ing effects on viral infection [21,27,28]. One potential explanation
for this is that all three structures were solved using monomeric CA
NTD, whereas a fully assembled HIV-1 capsid is comprised
exclusively of multimeric CA, predominately hexamers, containing
both NTD-NTD and NTD-CTD interfaces [31]. Understanding
the effect of ligand binding on intact capsid is of particular interest as
there are conflicting reports on the effect of PF74 and BI-2 on capsid
stability [28,29,32].
Here we report crystal structures of assembled HIV-1 CA
hexamers with peptides comprising the linear binding epitopes of
NUP153 and CPSF6 and the two antiviral compounds PF74 and
BI-2. These structures reveal that the first three ligands make
interactions both within and between CA subunits, using a
previously unknown binding site at the NTD-CTD interface that
significantly increases binding to CPSF6 and PF74 and is required
for NUP153 interaction. NUP153, CPSF6 and PF74 utilize a
distinct sub-set of residues within this site, providing a molecular
basis for their associations with capsid and the resulting effects on
HIV-1 infection.
Results
CPSF6, NUP153 and PF74 exhibit preferential binding to
hexameric CA
CPSF6, PF74 and BI-2 have all been shown to interact directly
with HIV-1 CA NTD by isothermal titration calorimetry (ITC)
[21,27,28], whilst NUP153 from cell lysate has been shown to co-
sediment with His-tagged CA protein [20]. Crystal structures of
CPSF6, PF74 and BI-2 bound to monomeric CA-NTD all show
interaction with the same binding site, at the base of the CypA-
binding loop and between helices 3, 4 and 5. However, the pheno-
types observed upon binding to each ligand are different. NUP153
depletion does not affect reverse transcription but blocks nuclear
entry [22]. Expression of CPSF6 lacking its nuclear localisation
sequence (CPSF6DNLS) blocks reverse transcription [3,30], as
does PF74, while BI-2 inhibits infection post-reverse transcription
[28,29,30]. To attempt to explain how these diverse phenotypes
are achieved, we carried out interaction studies using a CA that
can be assembled into stable hexamers through the formation of
engineered disulfide bonds at the NTD-NTD intrahexameric inter-
face [33]. In each case we compared binding to monomers by reduc-
ing hexamers with DTT. Previously, we have shown that a 15-mer
peptide from CPSF6 containing a central FG motif is sufficient for
binding to CA NTD [21]. Using a similar strategy, an FG-containing
17-mer from NUP153 was synthesized, based on published co-
sedimentation data [20]. The two peptides (CPSF6313–327 with
sequence PVLFPGQPFGQPPLG and NUP1531407–1423 with
sequence TNNSPSGVFTFGANSST) were then tested for binding
to intact and dissociated CA hexamer alongside PF74 and BI-2.
Unless otherwise stated, all experiments describing ‘CPSF6’ or
‘NUP153’ refer to these peptides. Binding of all four ligands was
observed to monomeric CA, confirming previous monomer stud-
ies with CPSF6313–327, PF74 and BI-2 and showing that the
NUP1531407–1423 peptide is sufficient for direct binding (Figure 1A).
Comparison to matched data with hexamer however reveals that,
with the exception of BI-2, each ligand interacts with significantly
improved affinity to hexameric CA compared with monomeric CA.
CPSF6 binds with a 14-fold increased affinity to hexamer and PF74
with a 22-fold increase. This difference was most dramatic with
NUP153, which showed comparable affinity to the hexamer as
CPSF6 but negligible binding to monomeric CA. This result is in
Author Summary
The early steps of HIV-1 infection are poorly understood, in
part because of the difficulty in obtaining high-resolution
information on encapsidated virus and its interaction with
host cofactors. This, in turn, has made it difficult to design
effective anti-capsid (CA) drugs. In our present study, we
have used stabilized hexamers of HIV-1 CA to obtain
complexed crystal structures with two cellular cofactors
that are important for HIV-1 infection. These structures and
accompanying virology reveal an essential interface in the
capsid of HIV-1 that is lost upon viral uncoating. This
interface is used to recruit both the nuclear targeting
cofactor CPSF6 and NUP153, a nuclear pore component
that facilitates nuclear entry. The high-resolution informa-
tion provided by these structures reveals that the interface
is degenerate and CA mutations can be made that
selectively perturb sensitivity to each cofactor. This
interface is also competed by two antiviral drugs, PF74
and BI-2, whose different mechanisms of action are not
fully understood. We show that PF74, but not BI-2, binds
across monomers within multimerized capsid affecting an
inter-hexamer interface that is crucial for maintaining
intact virions and that the addition of saturating concen-
trations of PF74 causes an irreversible block to viral reverse
transcription.
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contrast to predictions that oligomerization does not affect NUP153
binding and that there is efficient binding to monomeric CA [20].
This is a particularly significant result because it suggests that HIV-1
docks to the nuclear pore as some form of assembled capsid.
Although the multimerisation status of capsid at the nuclear pore is
unknown, our data indicates that if the capsid disassembles prior to
Figure 1. Binding of HIV-1 hexamer to CPSF6, NUP153, PF74 and BI-2. (A) ITC binding isotherms of HIV-1 hexamer titrated into different ligands
in either the presence or absence of DTT. For both CPSF6 and NUP153, a peptide corresponding to residues 313–327 or 1407–1423 respectively was
used. (B) Titration of HIV-1 cofactors CPSF6 and NUP153 into hexamer in the presence of pharmacologic inhibitors. Thermodynamic parameters are
indicated for interactions displaying a clear binding isotherm; approximate affinities are shown for weak interactions; NB = no binding detectable.
doi:10.1371/journal.ppat.1004459.g001
Structures of HIV CA with Essential Cofactors and Antivirals
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locating to the nuclear pore then the ability of HIV-1 to engage
NUP153 would be significantly compromised.
Comparison of the affinities with which the different ligands bind
CA reveals several important points. First, CPSF6 and NUP153
bind hexamer with identical affinities, although binding to mono-
mer is different suggesting that they make different interactions.
Second, PF74 and BI-2 have identical affinities to monomeric
capsid but PF74 binds hexamer with a 10-fold higher affinity than
BI-2. Indeed, BI-2 binds hexamer with similar affinity to monomer
(within 2-fold; Figure 1A). Third, the finding that PF74 actually
binds capsid with an affinity of ,0.1 mM explains why its potency in
infection experiments is significantly greater than its published
affinity. Previously, we have shown that PF74 competes with CPSF6
for binding to monomeric NTD CA [21]. Competition experiments
show that both PF74 and BI-2 also inhibit CPSF6 binding to
hexamer (Figure 1B). Furthermore, PF74 and BI-2 also prevent
NUP153 binding to hexamer, suggesting that the drugs are
competitive inhibitors of both host cofactors (Figure 1B).
Cofactors CPSF6 and NUP153 bind a hexamer-specific
interface formed between two adjacent monomers
To understand how CPSF6 and NUP153 interact with hexa-
meric CA we determined X-ray crystal structures with the same
peptide ligands used in the ITC studies. Crystals of each complex
were obtained in two different spacegroups, hexagonal (P6) and
orthorhombic (P212121) (Table 1), similar to those reported for the
uncomplexed CA hexamer [31]. The structures reveal that the
binding pocket identified for CPSF6 in CA NTD is actually part of
a much larger protein-protein interface that also accommodates
NUP153 and is present only in assembled CA (Figure 2 and 3).
The complete binding site is formed by NTD helices 3 and 4 of
one CA monomer (referred to as the ‘first site’) and NTD helices 2
and 7 and CTD helices 8 and 9 from an adjacent monomer
(referred to as the ‘second site’). The cofactor interface incorpo-
rates a structurally dynamic region involving CTD helices 8 and 9
that was observed to adopt two distinct conformations in the
orthorhombic crystal structure of the uncomplexed hexamer
(Figure 3). Comparison to CPSF6 and NUP153 complexes solved
in the same orthorhombic form reveals that these cofactors selec-
tively bind to one of these conformations, which we have termed
‘open’ (Figure 3 and Supplementary Figure S1). In the ‘open’
conformation, helices 8 and 9 are of equal length and separated by
a single residue. In the alternative ‘closed’ conformation ,1/3 of
helix 9 has unwound, creating a loop of six residues (177–182) that
folds back into the binding site, partially occluding it. Binding of
CPSF6 and NUP153 to hexamer in the ‘closed’ conformation is














Space group P 6 P 212121 P 6 P 212121 P 6 P 6
Cell dimensions
a, b, c (Å) 91.5, 91.5, 57.0 135.1, 135.9, 208.2 91.5, 91.5, 57.0 135.4, 138.1, 211.9 91.2, 91.2, 56.3 90.9, 90.9, 56.6













Rmerge 0.266 (0.973) 0.069 (0.588) 0.101 (0.909) 0.085 (0.581) 0.186 (0.843) 0.164 (0.451)
I/sI 4.6 (2.0) 11.7 (2.2) 7.3 (1.6) 8.6 (1.7) 7.7 (2.0) 7.2 (3.0)
Completeness (%) 100.0 (100.0) 95.1 (97.6) 95.1 (95.8) 97.0 (97.3) 98.1 (87.0) 93.4 (72.5)




























Protein 1701 19958 1710 19269 1608 1565
Ligand/ion 1 - - 1 33 26
Water 147 - 200 - 148 76
B-factors
Protein 21.5 87.0 24.3 78.8 30.0 36.6
Ligand/ion 20.5 - - 58.1 21.8 42.5
Water 32.3 - 33.7 - 33.4 33.5
R.m.s. deviations
Bond lengths (Å) 0.004 0.004 0.005 0.004 0.005 0.006
Bond angles (u) 0.837 0.739 0.877 0.662 0.924 0.918
Statistics are given for the six structures, titled by complex followed by the spacegroup in parentheses. Values in parentheses are for the highest-resolution shell.
doi:10.1371/journal.ppat.1004459.t001
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prevented by steric clashes with loop177–182. A consequence of
cofactor binding may therefore be to alter capsid conformational
dynamics and drive equilibrium towards an ‘open’ conformation
at the CTD-CTD or hexamer-hexamer interface.
The ‘open’ and ‘closed’ conformations of the co-factor binding
site represent two alternate states of the hexamer. The ‘open’ con-
formation comprises a stable helix-loop-helix motif whereas the
‘closed’ conformation is held in place by R173 through a planar
stacking interaction with Q179 and hydrogen bond with N57. A
conformationally dynamic interface will influence the entropy of
binding, therefore the complexation of hexamer with CPSF6,
NUP153 and PF74 would be expected to occur with a different
change in entropy than BI-2. Examination of the ITC data reveals
that this is indeed the case and binding of BI-2 occurs with a
negative DS whereas it is positive with the other ligands (Figure 1A).
This interpretation is supported by NMR experiments, which show
that loop177–182 isomerizes between two discrete conformers [34].
The two conformations are not equally energetically stable and one
of the conformers is only transiently populated (,7% at equilibrium).
CPSF6 and NUP153 have been identified as disparate host
cofactors that nevertheless share a common binding site on HIV-1
CA. However, whilst they share interactions within the first,
Figure 2. Crystal structures of CPSF6313–327 (A) and NUP1531407–1423 (B) FG-containing peptides in complex with HIV-1 hexamer. The
P6 crystal form is shown, with the six subunits of the HIV-1 capsid generated by crystallographic symmetry. The capsid is shown in a ribbon
representation with each monomer colored differently. Atoms comprising the cofactor peptides are shown as spheres, with each peptide colored
separately. There are six cofactor binding sites per hexamer and six bound cofactor peptides. For each structure two views are shown, related by 906.
doi:10.1371/journal.ppat.1004459.g002
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monomeric, binding site they make distinct interactions to the
second site, in the context of hexameric CA (Figure 4). Within one
monomer, CPSF6 interacts with N53, L56, N57, M66, Q67, L69,
K70, I73, N74, A77, S102, A105, G106, T107, T108 and Y130
(Figure 5A). Of these interactions, binding and restriction studies
have confirmed an important role for N57, M66, K70, N74 and
Figure 3. CPSF6 and NUP153 bind a multi-subunit interface in HIV-1 hexamer. (A) Two monomers from the CPSF6 P212121 complexed
structure are shown in gray and teal, with the CPSF6 peptide in yellow and the NUP153 peptide from the P212121 complexed structure superposed
and shown in pink. The helices that comprise the binding site are numbered. (B) Two monomers from the uncomplexed P212121 hexamer structure
(3H4E) showing representative helices 8 and 9 in ‘open’ (teal) and ‘closed’ (green) states are superposed. The side-chain of residue Q179 is shown in
stick representation. (C) CPSF6 binding site in the P212121 structure, with the peptide shown in yellow and subunits colored as above. (D) NUP153
binding site in the P212121 structure, with peptide shown in pink and subunits colored as above. CPSF6 and NUP153 preferentially bind an open
conformation of helices 8 and 9.
doi:10.1371/journal.ppat.1004459.g003
Structures of HIV CA with Essential Cofactors and Antivirals
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T107 [21]. Meanwhile, NUP153 interacts with residues N53, L56,
N57, Q63, M66, Q67, L69, K70, I73, A105, G106, T107 and
Y130 (Figure 5B). There was no observed interaction between
NUP153 and CA N74, supporting findings that mutation N74D
specifically abolishes CPSF6 binding [20,21]. The overlap in
residue usage reflects similarities in the way in which CPSF6 and
NUP153 engage capsid within the monomeric binding site. Pre-
viously, we have shown that CPSF6 residue F321, which occupies
the same pocket as the phenyl rings of PF74 and BI-2, is critical for
interaction of CPSF6 with capsid [21]. We confirmed that CPSF6
F321 is critical for hexamer binding, as mutation to alanine
abolishes interaction (Supplementary Figure S2). In NUP153, an
equivalent interaction is mediated by F1417, which superposes
closely with CPSF6 F321 (Figure 3A and Figure 5A and B). ITC
binding experiments confirm that this NUP153 residue is essential,
as F1417A has no measurable binding to hexamer (Supplementary
Figure S2). The importance of F321 in CPSF6 and F1417 in
NUP153 is in part to orient the main-chain for hydrogen bond
interactions with the side-chain of N57 (Figure 5A and B). This
most likely explains why capsid mutant N57A was identified as
critical for co-immunoprecipitation of NUP153 with CA NTD
and for restriction by a TRIM-NUP153 fusion [20]. Within the
monomer binding site, NUP153 makes unique contacts with Q63,
while CPSF6 makes unique contacts with N74, A77, S102 and
T108 (Figure 5A and B). The unique interaction of CPSF6 with
N74 explains why mutation N74D prevents binding to CPSF6 but
allows co-immunoprecipitation with NUP153 and remains sensi-
tive to TRIM-NUP153 restriction [20].
Outside of the phenylalanine binding pocket, the two ligands
form distinct interactions with hexameric capsid. Both cofactors
make interactions across neighbouring hexamers but while CPSF6
contacts the CTD of the second monomer, NUP153 interacts
predominantly with the NTD (Figures 3 and 5). The ligands diverge
after the shared phenylalanine, with CPSF6 residues 315–319 inter-
calating between helices 4 and 9 in neighbouring monomers and
making contacts with residues Y169, L172, R173, Q179, K182,
N183 and T186, including hydrogen bonds with Q179 and K182
(Figure 5C). As these second site contacts are driven by CPSF6
residues that interact via their main-chain or through hydrophobic
burial, their importance is difficult to assess through side-chain
mutation. However, mutants F316A and P317A both have signifi-
cantly reduced binding affinity for hexamer as measured by ITC,
while the introduction of charged residues by either P317D or
G318R abolishes binding completely (Supplementary Figure S2).
The dramatic effect of G318 mutation on CPSF6 binding correlates
with the reduced ability of NLS deleted CPSF6 mutant G318A to
restrict HIV-1 [35]. To complement our studies using different
CPSF6 peptides, we tested the sensitivity of interface mutants to
restriction by CPSF6DNLS. Previously, we have shown that CPSF6
interface mutants N57A, Q67A, K70A, N74D and T107A are all
resistant to restriction by CPSF6DNLS [21]. Of the remaining
interface residues, A77D and T108A were noninfectious whilst
S102D and K182R escaped restriction (Figure 6A). Q179P was still
sensitive to restriction by CPSF6DNLS; however, its hydrogen bond
to the carbonyl oxygen of P317 may simply have been replaced by a
hydrogen bond with the nearby side-chain of N183, thus main-
taining interaction.
Unlike CPSF6313–327, which forms almost a cyclised structure,
NUP153 residues 1410–1417 form an extended linear conforma-
tion that runs from F1417 across the face of CA helices 2 and 7
from the second monomer. NUP153 interacts with helix 2 residues
P34, I37, P38 and S41 and helix 7 residues I135, L136, N139,
Figure 4. CPSF6 and NUP153 interact with distinct sets of CA residues within the hexamer interface. A molecular surface representation
of the CPSF6 and NUP153 binding site in hexameric capsid is shown in gray. The interface is formed between two neighbouring monomers and is
shown in a similar orientation to Figure 3. The CPSF6 (A) and NUP153 (B) peptides in the different complexed structures are shown in yellow and pink
respectively. The binding ‘footprint’ of each ligand is shown in red for CPSF6 and yellow for NUP153. The footprint was calculated using PISA [44] and
is defined as residues containing atoms that become desolvated upon binding (i.e. are within 1.4 Å of the ligand).
doi:10.1371/journal.ppat.1004459.g004
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K140, V142 and R143. NUP153 also interacts with the end of
helix 8, where it meets helices 2 and 7, and hydrogen bonds with
R173, Q176 and A177. Interactions between NUP153 and the
second monomer are essential, as shown by the ITC experiments
in which NUP153 binds hexamer but not monomer (Figure 1A).
NUP153 residues T1416, F1415, S1412 and P1411 all make impor-
tant interactions with the second site. The side-chain of T1416
interacts directly with CA R173 and with CA Q63 via a water and
T1416A abolishes binding by ITC (Supplementary Figure S2 and
S3). F1415 forms a hydrophobic interaction with CA P38 and loss of
this interaction (F1415A) also prevents binding. S1412 forms poten-
tial hydrogen bonds with CA A177 and Q176. Mutation S1412A
has little impact on the affinity to hexamer but this is not unexpected
as Q176 interaction is via the main-chain (Supplementary Figure S2).
Figure 5. CPSF6 and NUP153 interact both within and between CA monomers. Detailed views of the interactions between the ligands and
the binding site within hexameric capsid are shown. In each case two adjacent monomers of the hexamer are colored gray and teal, with the side
chains of specific contacting residues displayed and labelled in standard text. Potential hydrogen bonds with ligands are indicated by dashed lines.
The upper panels (A and B) focus on interactions that occur in the first binding site (within one monomer), while the lower panels (C and D), show
interactions in the second binding site (with the second monomer). CPSF6 is shown in yellow and NUP153 in pink, with important ligand residues
labelled in bold and italic text.
doi:10.1371/journal.ppat.1004459.g005
Structures of HIV CA with Essential Cofactors and Antivirals
PLOS Pathogens | www.plospathogens.org 8 October 2014 | Volume 10 | Issue 10 | e1004459
Finally, P1411 forms a hydrophobic interaction with the side-chain
of R143 and mutation P1411A decreases binding by approximately
10-fold (Supplementary Figure S2). Only the central 9 residues of
the NUP153 peptide have a rigid structure in the complexed crystal
structure (1407-TNNSPSGVFTFGANSST-1423). This suggests
that the chosen peptide is sufficient to define the important contacting
residues within this linear epitope. We cannot rule out that there
may be other contacts outside of this region in the context of full-
length NUP153 protein, however our data together with published
work [20] suggests that a short FG-containing sequence is both
necessary and sufficient for binding. In this respect, NUP153 and
CPSF6 are similar in using a linear binding motif to interact with
hexameric CA, anchored around a core phenylalanine but other-
wise mediating diverse contacts.
The fact that CPSF6 and NUP153 make specific contacts with
hexameric CA suggests that it is possible to selectively abolish
binding to each ligand, in a similar manner to mutation N74D in
the first site. Within the second site, NUP153 makes specific con-
tacts with capsid residues P38 and R143, while CPSF6 makes
specific contacts with S102 and K182. We mutated these residues
and tested their sensitivity to restriction by CPSF6DNLS and
TRIM-NUP153 and their dependence on TNPO3. NUP153
specific mutants P38A and R143A retained sensitivity to both
CPSF6DNLS restriction and TNPO3 dependence (Figure 6A&B).
However, CPSF6-specific mutants S102D and K182R rescued
virus from both CPSF6DNLS restriction and TNPO3 dependence
(Figure 6A&B). Meanwhile, mutants S102D and K182R were
sensitive to TRIM-NUP153 while R143A escaped restriction
(Figure 6C). In agreement with published data, mutant P38A had
increased sensitivity to TRIM-NUP153, suggesting that the alanine
substitution enhances binding (Figure 6C and [20]). These results
confirm that P38A, S102D, R143A and K182R are cofactor selec-
tive mutants. Furthermore, mutants R143A and K182R support the
functional importance of the second site for NUP153 and CPSF6
interaction respectively.
PF74 and BI-2 have distinct binding mechanisms
The discovery that the binding site for CPSF6 and NUP153 is
actually an extended interface that is formed at the junction
between two monomers in the hexamer suggested that the inter-
action with PF74 and BI-2 should be re-examined. In particular,
we wondered whether the two drugs engage hexamer differently,
which would explain the higher affinity of PF74 and its different
activity. Complexed structures of each drug with hexamer were
solved in a P6 spacegroup and their mode of binding compared
(Table 1). As expected, each has a phenyl ring that superposes
almost exactly within the previously identified pocket in the NTD,
making an equivalent interaction to F321 in CPSF6 and F1417 in
NUP153 (Figures 5 and 7). However, this motif and hydrogen
bonds with the side-chain of N57 are the only features shared by
all four ligands. Uniquely amongst the ligands, BI-2 interacts solely
within the NTD of each subunit (Figure 7A & C). Accordingly, the
hexamer:BI-2 complexed structure is very similar to that of the
published monomer structure with the related compound BI-1
[28]. The most significant difference between the two is that the
hydroxyphenyl moiety in BI-2, which replaces the piperidine ring
in BI-1, facilitates hydrogen bonding to N74 (Figure 7E). This BI-
2 specific interaction may explain why it binds almost 10-fold
more tightly than BI-1 to CA NTD [28]. Most significantly, the
absence of any BI-2 interactions outside of the monomer explains
why it does not bind hexamer with a substantially higher affinity,
unlike PF74.
Analysis of the hexamer:PF74 structure reveals that, in addition
to making contacts within the NTD of one monomer, PF74
interacts with the CTD of an adjacent monomer (Figure 7B & D).
This additional interaction was unexpected and could not have
been predicted by modelling the structure of PF74:CA NTD com-
plex structure (pdb 2XDE) onto the hexamer structure, because
the orientation of the 2-methylindole moiety has changed in the
hexamer complex (Figure 7F). As a result of this reorientation, the
Figure 6. Sensitivity of CA mutants to restriction by CPSF6DNLS
or TRIM-NUP153 or depletion of TNPO3. Titres of VSV-G pseu-
dotyped GFP-encoding HIV-1 vectors bearing wild type or mutant CA on
HeLa cells expressing empty vector (EV) or CPSF6DNLS (A), control
knockdown cells (shControl) or cells depleted of TNPO3 (shTNPO3) (B),
control knockdown cells (shControl) or cells expressing empty vector (EV)
or TRIM-NUP153 (C). In each case infectivity is plotted as infectious units
(IU)/ng p24. The data are representative of two independent experi-
ments, each using three different virus doses.
doi:10.1371/journal.ppat.1004459.g006
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2-methylindole moiety forms a planar stacking interaction with the
side-chain of R173 (Figure 7B). Cation-p interactions such as
those between arginine and tryptophan can contribute significant-
ly to binding energy, and computational studies suggest that in a
solvent-accessible environment they are twice as strong as a typical
salt bridge [36]. This indole re-orientation not only allows stacking
with R173, it also reveals a hydrogen bond between the indole NH
and Q63 (Figure 7B). Whether interaction between Q63 and
PF74, despite being absent in the monomeric crystal structure,
occurs during binding of PF74 to monomeric CA is unclear; there
may be a requirement for hexamer both to supply R173 to orient
the 2-methylindole and to position the side-chain of Q63 for
hydrogen bonding to PF74. Together, these extra interactions seen
in the context of the hexameric complex structure most likely
account for the significant increase in affinity seen on binding of
PF74 to hexamer vs. monomeric CA (Figure 1A).
As with the P6 structures of uncomplexed hexamer [31] and
hexamer in complex with the peptide ligands (Supplementary
Figure S1), the CTD region around the N-terminus of helix 9 was
poorly ordered in the P6 hexamer:drug structures (Figure 7). Nev-
ertheless, superposition of the P6 hexamer:PF74 structure on the
orthorhombic uncomplexed hexamer structure showed that the
interaction between PF74 and CA directly displaces the stacking
interaction between R173 and Q179 that stabilises the ‘closed’
interface conformation, with the 2-methylindole taking the place
of the glutamine side-chain. For this reason, PF74, like CPSF6 and
NUP153, cannot bind to the hexamer when CTD helices 8 and 9
are in the ‘closed’ conformation (Supplementary Figure S4),
although we cannot rule out the possibility of additional interactions
between this region and the drug. In contrast, the closed confor-
mation is not predicted to occlude BI-2 binding.
The different PF74 orientations in the monomer versus
hexamer structures as well as the resulting new interactions raise
the question of what capsid contacts are essential for drug binding.
To investigate this we adopted a chemical genetics approach to
avoid the pleiotropic effects of capsid mutants. We first attempted
to assess the contribution of the 2-methylindole group by removing
it either before or after the amine. No binding to CA NTD could
be observed by ITC for either compound lacking the 2-
methylindole (Figure 8, PF74_1 and PF74_2). This result suggests
that hydrogen bonding to N57 is not sufficient for CA interaction
and that Q63 and R173 are important for PF74 binding. To
dissect the contributions of interaction with Q63 and R173 we
replaced the 2-methylindole with pyrrole, furan, thiophene and
tetrahydrofuran moieties that have altered aromaticity and hydro-
gen bond propensities (Figure 8). The pyrrole-containing com-
pound (PF74_3) lacks the 6-membered ring found in 2-methylindole
but retains the hydrogen-bond donor. This compound had a 46-fold
reduction in affinity to hexamer, indicating that much of the
enhanced binding to hexamer was lost (Figure 8; PF74_3). The
furan and thiophene (PF74_4 and 5) compounds, which have a
hydrogen bond acceptor instead of donor, interacted with hexamer
with similarly weakened affinities as the pyrrole (a reduction of
94-fold and 54-fold respectively). This is probably because the
electronegative element coordinates a glutamine (Q63), which is
able to hydrogen-bond to both hydrogen donors (N) and hydrogen
acceptors (O, S). Finally, the tetrahydrofuran derivative has lost
aromaticity and therefore the ability to form cation-p interactions
and has the weakest affinity for hexamer, reduced by .1000-fold.
These results suggest that the binding of PF74 to hexamer is
mediated primarily by a stacking interaction with R173.
The PF74 derivatives described above also provided an oppor-
tunity to test the correlation between compound affinity and
potency in infection experiments. As noted earlier, there is a
discrepancy in the literature between the published affinity of PF74
and its potency and also between the potency of PF74 and BI-2.
When tested, all PF74 derivatives with weaker affinity to hexamer
had a correspondingly weaker ability to inhibit HIV-1 infection
(Figure 9A). Plotting the IC90 for infection against compound
affinity gives a Pearson correlation coefficient of 0.9928 and a P-
value of 0.0007, demonstrating that the relationship between
affinity to hexamer and potency is highly significant (Figure 9B).
These results also suggest that a different affinity for capsid is the
reason why PF74 is a more potent inhibitor than BI-2 (Figure 9C).
Indeed, when data are normalized using our measurements for drug
affinity to hexamer it is apparent that the higher affinity of PF74
completely accounts for the difference between the compounds
(Figure 9D).
Finally, we investigated whether our structural and biophysical
data could also explain the different phenotypic effects of PF74
and BI-2 on infection. PF74 has a curious inhibition profile in
which there is an initial dose-dependent decline in infection, fol-
lowed by a plateau over a ,10-fold concentration range then a
second inhibition curve (Figure 9C). Parallel infection and qPCR
experiments reveal that the first inhibition, at lower drug concen-
trations, is not associated with any block to viral reverse
transcription (Figure 9E). In contrast, the second inhibition, at
high drug concentrations, occurs in parallel with a dose-dependent
inhibition of reverse transcription. When the data are re-plotted
taking into account the measured affinity of PF74 for hexameric
CA and expressed as the predicted fraction of unoccupied sites per
whole viral capsid, the second block to infection can be seen to occur
only at drug concentrations where all six sites in a majority of
hexamers become occupied (,5o free sites per capsid) (Figure 9F).
One mechanism by which PF74 might affect reverse transcrip-
tion at high occupancy is by altering capsid stability. PF74 has
been reported to destabilize the capsid [29] and our structures
suggest a mechanism by which this could occur, namely by
inducing changes at the CTD-CTD interface around helices 8 and
9 that hold hexamers together. To test this hypothesis we
examined whether PF74 inhibition is reversible. In wash-out
experiments we observed that inhibition of infection by concen-
trations of PF74 within the first (1 mM) and second (10 or 30 mM)
block could be completely and partially reversed, respectively;
however, the block to reverse transcription that PF74 mediates at
high concentrations was largely irreversible (Figure 9G). To deter-
mine whether there is a time window post-infection during which
PF74 must be added for efficacy, we performed a time-of-addition
Figure 7. HIV-1 CA hexamer complexes with pharmacologic ligands BI-2 and PF74. Two monomers from hexameric structures complexed
with BI-2 (A) and PF74 (B) are shown in a close-up view of the binding site, with one monomer in gray and a second monomer in teal. BI-2 is shown in
orange and PF74 in green. Important CA interacting residues are shown as sticks and putative hydrogen bonds indicated by dashed lines. Ligplots
[45] are shown for BI-2 (C) and PF74 (D) in which a ball-and-stick representation of the ligand is shown together with CA residues that contribute a
hydrogen bond. Other interacting CA residues are indicated with a red-dashed semi-circle. Circled areas indicate interacting CA residues that are
shared between both structures. (E) Superposition of the BI-2:hexamer complex (BI-2 in orange) with the previously solved BI-1:CA-NTD complex [28]
(BI-1 in blue). The secondary structure of the superposed monomers from each structure is shown in gray, while capsid side-chains from only the
hexamer complex are depicted. The adjacent monomer in the hexamer complex is shown in teal. (F) Superposition of the PF74:hexamer complex
(PF74 in green) with the previously solved PF74:CA-NTD complex [27] (PF74 in slate). The capsids are colored as in (E).
doi:10.1371/journal.ppat.1004459.g007
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experiment. We found that at both low and high doses PF74
quickly lost inhibition if addition was delayed, such that by
10 hours post-infection almost all efficacy was lost (Supplementary
Figure S5A). This is further evidence that PF74 acts at a post-entry
but pre-integration stage of viral infection. To determine whether
the reversibility of PF74 inhibition is affected by the time of drug
addition, we repeated our washout experiments but adding PF74
2 hours post-infection rather than coincident with virus. Levels of
inhibition were decreased when drug addition was delayed, as
expected, but the pattern of reversibility stayed the same
(Supplementary Figure S5B&C). Namely, low dose PF74 inhibi-
tion was reversed upon washout but high dose inhibition was not.
Taken together, these data fit a model in which PF74 inhibits
HIV-1 infection at low dose by competing for cofactor binding
and at high dose by inducing an irreversible block to reverse
transcription, possibly as a result of irreversible changes to the
capsid ultrastructure. This model agrees with published data in
which the potency of PF74 at low doses is dependent upon the
expression of cofactors in the cell and on capsid. Depletion of
TNPO3 or NUP153 reduces PF74 inhibition at low but not high
doses, as do CA mutants such as N74D or the expression of
TRIM-NUP153 [20,37]. The fact that the low dose PF74 block to
infection is not cumulative with the inhibition arising from
perturbing these cofactors is consistent with it acting as a
competitive inhibitor. Unlike PF74, BI-2 has not been observed
to block reverse transcription [28]. Based on the above data, this
could either be due to the fact that insufficiently high drug
concentrations have been tested to achieve complete occupancy or
because it has a different mode of binding. Unfortunately, BI-2 is
not soluble at concentrations that would allow this to be tested.
However, the weaker affinity of BI-2 for hexamer is not itself a bar
to inhibiting reverse transcription, as PF74 derivatives that have
weaker affinities than BI-2 block reverse transcription if added at
sufficient concentration (Figure 9H).
Figure 8. Structures of PF74 derivatives used in this study and their affinities of binding to CA. Affinities of binding to hexamer as
measured by ITC are shown. No binding was detected between PF74_1 and PF74_2 to HIV-1 CA NTD, therefore the interaction with hexamer was not
tested.
doi:10.1371/journal.ppat.1004459.g008
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Figure 9. Inhibition of HIV-1 infection by BI-2, PF74 and PF74 derivatives. (A) Titration of PF74 or indicated derivatives onto HeLa cells
infected with VSV-G pseudotyped GFP-encoding HIV-1 vector. For each titration, infectivity is normalised to the level in the absence of inhibitor
(100%). (B) Correlation between the IC90 values derived from (A) and the Kd values for purified hexameric capsid as calculated by ITC (Figure 8). The
values are highly correlative with a Pearson correlation coefficient of 0.9928 and a P-value of 0.0007. (C) Titration of PF74 or BI-2 onto cells infected
with VSV-G pseudotyped GFP-encoding HIV-1 vectors, normalized as in (A). (D) Data from (C) but with infectivity plotted against drug concentration
divided by affinity to hexamer as calculated by ITC. (E) Titres of VSV-G pseudotyped GFP-encoding HIV-1 vectors 48 h post-infection and levels of
reverse transcription (RT) 4 h post-infection under conditions of PF74 inhibition. For both measures, data are normalized to the values obtained in the
absence of inhibitor. (F) Data from (E), except plotted against the calculated level of CA occupancy by PF74. The occupancy was calculated assuming
that there are 1500 free sites per capsid and that number of free sites = 1500(12([PF74]/Kd[PF74])) (G) Infectivity and reverse transcription in cells
infected in the presence of PF74 (wash) or when removed after four hours (wash out). Reverse transcription was then measured after a further 4 h,
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Discussion
Four ligands for HIV-1 – two antiviral drugs and two host
cofactors – have been shown to bind a shared binding site in
monomeric CA. Here we show that this binding site is actually
part of a larger protein-protein interface that only exists in the
context of hexameric CA. Identification of this interface has
revealed that, while there are common interactions principally
involving CA N57, there are also ligand-specific contacts. An
example of such a contact is N74, which our results show is
required for binding to CPSF6 and not NUP153. Other CA
residues that are important for binding specifically to CPSF6
include A77, S102, T108, Q179 and K182. Of these, we have
shown that S102D and K182R escape restriction by CPSF6DNLS,
are insensitive to TNPO3 depletion and sensitive to TRIM-
NUP153. Conversely, NUP153 makes specific CA interactions that
are not used by CPSF6, including with P38, S41, Q63 and R143. In
agreement with this, we have identified R143A as a capsid mutant
that is susceptible to TNPO3 depletion, sensitive to restriction by
CPSF6DNLS and insensitive to TRIM-NUP153.
Our data support a model in which both CPSF6 and NUP153
are important HIV-1 cofactors. Engagement of CPSF6 is not
required for HIV-1 infection in transformed cell lines [2] but is
tightly correlated with dependence on the nuclear entry cofactors
TNPO3, NUP153 and NUP358 [38]. There are as yet no
examples where perturbing the recruitment of these nuclear entry
cofactors (through depletion or CA mutation) reduces infection of
viruses that cannot engage CPSF6. Thus, interaction of the capsid
with CPSF6 commits HIV-1 to the use of active nuclear pores (as
defined by cofactor sensitivity). An important question is therefore
why the virus utilizes this pathway if it is not required for infection.
However, there are significant consequences for viruses that fail to
engage with nuclear entry cofactors. Infection of primary monocyte-
derived macrophages depleted of CPSF6 reveals HIV-1 to innate
immune sensors, leading to induction of an antiviral state and
abrogation of HIV-1 replication [3]. In cells in which innate
immune sensing mechanisms are not activated, viruses that are
independent of nuclear entry cofactors have altered HIV-1 inte-
gration site targeting [9,11]. Moreover, HIV-1 appears to be under
selective pressure in vivo to retain CPSF6 binding [38]. It is
noteworthy that CPSF6 and NUP153 not only appear to function in
the same nuclear import pathway but also share the same CA
binding site. This is reminiscent of CypA and NUP358, which
similarly compete for binding [16]. Whether this reflects a sequen-
tial pathway, with CypA and CPSF6 operating upstream of
NUP358 and NUP153, and what the purpose of this might be,
remains unclear. Alternatively, we cannot rule out the possibility
that CPSF6 engages HIV-1 during passage through the nuclear
pore, after NUP153.
The structures presented here allow a protein interaction role to
be ascribed to many of the CA mutants that have formed the basis
for dissecting HIV-1 post-entry behaviour. However, several CA
residues remain for which we cannot currently assign a role in
cofactor binding but that nevertheless display specific post-entry
defects. Examples of this include E45 and R132, which are located
in relative proximity at the top of helices 2 and 7 respectively,
between the CPSF6/NUP153 and CypA binding sites. Mutation
of R132 results in reduced reverse transcription kinetics [13] and
TNPO3 dependence [19] and, in the case of E45A, partial resis-
tance to PF74 [37]. These mutations may have a direct effect on
intrinsic capsid stability but they may also disrupt the conse-
quences of cofactor binding in an allosteric manner or alter inter-
actions with as yet unidentified cofactors. CPSF6 and NUP153
and the antiviral drug PF74 all bind an interface that includes
helices 8 and 9, previously shown to be flexible in both capsid
crystal structures and NMR studies [31,34]. The flexibility in this
region may represent a requirement for capsid to be dynamic but
it may also make the interface harder to target by restriction
factors, analogous to the ‘conformational masking’ employed by
gp120 to avoid neutralizing antibodies [39]. Our data suggest that
ligand binding is only possible when this region adopts an ‘‘open’’
conformation. The consequences of fixing this conformation in the
bound state may involve changes in capsid structure up to and
including uncoating. Indeed, this may explain why at saturating
doses of PF74 an irreversible block to infection is observed.
Materials and Methods
Production of hexamer, peptides and drugs
HIV-1 CA hexameric proteins, stabilized by engineered inter-
subunit disulfide bonds, were produced by assembly of recombi-
nant CA containing four amino acid substitutions, as previously
reported [33]. Peptides were synthesized by Designer Bioscience
(Cambridge, UK). BI-2 was provided by the Vanderbilt Institute
of Chemical Biology Synthesis Core, Vanderbilt University,
Nashville TN 37232-0412.
Synthesis of PF74 and derivatives
Compounds were synthesized using an amine intermediate as
previously described [21]. Reactions were monitored by thin layer
chromatography (TLC) and final products assessed for purity by
NMR and ESI-MS. For full details see Supplementary Text S1.
Isothermal Titration Calorimetry (ITC)
Hexamer protein was dialysed against ITC buffer (50 mM
TRIS pH 7.4, 150 mM NaCl) for experiments using intact
hexamer, or ITC buffer containing 1 mM DTT for experiments
with monomerized hexamer. The monomeric status of hexamer
dialysed against buffer containing DTT was confirmed by size
exclusion chromatography. Peptides were dissolved in the same
buffer as hexamer; NUP153 peptides were first dissolved in
DMSO to a concentration of 8 mM before diluting in buffer.
Drugs were dissolved in DMSO to a concentration of 5 mM,
before diluting in buffer. In all cases, hexamer (in the syringe) was
titrated into the peptide or drug ligand (in the cell), with the
exception of the competition experiments, whereby peptide
(400 mM) was titrated into hexamer (30 mM) in the presence of
drug (100 mM). Typical concentrations used were 600–800 mM
hexamer titrated against 60–80 mM peptide unless indicated
otherwise, and 200 mM hexamer titrated against 30 mM drug.
ITC experiments were conducted on a MicroCal ITC-200, and
data analyzed using Origin data analysis software (MicroCal).
Crystallization, data collection, structure determination
and refinement
Crystals were grown at 17uC in sitting well drops. In each case,
protein/ligand solution was mixed 1:1 with reservoir solution,
producing crystals within one week to one month. Crystallization
conditions were as follows: Hex:CPSF6 crystals were prepared
while infectivity was determined 48 h post-infection. (H) Levels of reverse transcription 4 h post-infection of HeLa cells in the presence of PF74 and its
derivatives at 206 IC9o drug concentrations.
doi:10.1371/journal.ppat.1004459.g009
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using 0.7 mM hexamer and 4 mM CPSF6 peptide (in 50 mM
TRIS pH 8.0) mixed with reservoir solution: (P6) 0.6M sodium
potassium tartrate tetrahydrate, 0.1M TRIS pH 8.5; and (P212121)
20% v/v PEG 300, 10% v/v glycerol, 5% w/v PEG 8K, 0.1 M
TRIS pH 8.5. Hex:NUP153 crystals were prepared using 0.4 mM
hexamer and 0.6 mM NUP153 peptide (in 50 mM TRIS pH 8.0,
100 mM NaCl) mixed with reservoir solution: (P6) 30% v/v PEG
400, 0.1 M CHES pH 9.5; and (P212121) 10% w/v PEG 8K, 0.1M
imidazole pH 8.0. Hex:PF74 and Hex:BI-2 crystals were prepared
by concentrating hexamer with a 2-fold molar excess of drug to a
final concentration of 0.4 mM hexamer (in 50 mM TRIS pH 8.0,
100 mM NaCl), before mixing with reservoir solution: (Hex:PF74)
0.2 M magnesium chloride, 8% w/v PEG 20K, 8% v/v PEG 550
MME, 0.1 M TRIS pH 8.5, 3% w/v 1,5-diaminopentane dihy-
drochloride; and (Hex:BI-2) 12% w/v PEG 4K, 0.1 M TRIS
pH 8.5, 3% v/v ethylene glycol. Crystals were cryoprotected with
20% 2-methyl-2-4-pentanediol or 20% ethylene glycol where nec-
essary, before flash-freezing in liquid nitrogen. Data were collected
in-house and at Diamond beamlines I04-1 and I24. Crystal data
collection and refinement statistics are provided in Table 1. The
datasets were processed using the CCP4 program suite [40]. Data
were indexed and scaled in MOSFLM and SCALA, respectively.
The structure was determined by molecular replacement in
PHASER using HIV-1 CA hexamer pdb 3H47 as a model for P6
structures, and pdb 3H4E as a model for P212121 structures.
Structural figures were prepared using PyMOL (MacPyMOL
Molecular Graphics System, 2009, DeLano Scientific LLC).
Cells and viruses
All cell lines were obtained from the American Tissue Culture
Collection (ATCC) unless otherwise stated. HeLa and Human
Embryonic Kidney 293 cells expressing the SV40 large T antigen
(HEK293T) cell lines were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal calf serum,
penicillin at 100 U/ml and streptomycin at 100 mg/ml. Replication
deficient VSV-G pseudotyped HIV GFP vectors were produced by
transfection of HEK293T cells with 1.5 mg HIV-1 Gag-Pol
expression plasmid (pCRV-1 [41]), 1.5 mg HIV-GFP encoding
plasmid (CSGW [42]) and 1 mg VSV-G glycoprotein expression
plasmid (pMD2G [43]) using Fugene-6 (Promega). Supernatant was
harvested 3 days post-transfection and passed through a 0.45 mm
filter. Mutagenesis of CA was performed using the QuikChange
method (Stratagene) against pCRV-1. Viral p24 levels were quan-
tified using Lenti-X p24 Rapid Titer Kit (Clontech).
Infection experiments
Infections were performed in the presence of 5 mg/ml polybrene
and GFP expressing cells were enumerated on a BD LSRII Flow
Cytometer (BD Biosciences) 2 days post-transfection after fixation
of cells in 4% paraformaldehyde. Where used, drugs dissolved in
DMSO or DMSO only were diluted in complete DMEM sup-
plemented with polybrene as above and added to cells shortly
before infection. For wash out experiments, cells were washed twice
with PBS 4 h post-infection and complete DMEM with DMSO
(wash out) or PF74 (wash) was added back to the cells. Stable
TNPO3 depletion experiments were performed by transducing
HeLa cells (16105) with retroviral vectors (pSIREN RetroQ)
expressing TNPO3-specific short hairpin RNA (shRNA). Cells were
selected with 10 mg/ml puromycin and stable cell-lines used in
infection experiments. For further details see [9]. For CPSF6DNLS
restriction experiments, a C-terminally deleted CPSF6 construct
(residues 1–504) was cloned from HeLa cDNA (accession number
NM_007007) and stably expressed following transduction of HeLa
cells with retroviral vector (pEXN). Cells were selected with 1 mg/ml
G418. And stable-cell lines used in infection experiments. For
further details see [3]. For TRIM-NUP153 restriction experiments,
constructs containing an internal HA tag or C-terminal HA tag (as
previously published [20]) or N-terminal HA tag were transduced
into HeLa cells and selected with puromycin or G418 respectively.
All three constructs contained NUP153 residues 896–1475 fused to
the C-terminus of the tripartite domains of TRIM5 (as described
[20]). A stable cell line expressing the N-terminal tagged construct
was then used in infection experiments. In all cases, infection was
carried out in 16105 HeLa cells at a multiplicity of infection (m.o.i.)
between 0.1–0.3 using VSV-G pseudotyped HIV GFP vector.
Quantitative PCR
For analysis of reverse transcription products, viral supernatant
was treated with 250 U/ml Benzonase (Millipore) for 20 min prior
to infection as above. DNA was extracted using DNeasy Blood and
Tissue Kit (Qiagen). GFP copies were quantified using primers
GFPF (CAACAGCCACAACGTCTATATCAT), GFPR (ATG-
TTGTGGCGGATCTTGAAG) and probe GFPP (FAM-CCGA-
CAAGCAGAAGAACGGCATCAA-TAMRA) against a standard
curve of CSGW on an ABI StepOnePlus Real Time PCR System
(Life Technologies).
Accession numbers
All structures have been deposited in the PDB. 4U0A:
Hex:CPSF6 P6, 4U0B: Hex:CPSF6 P212121, 4U0C: Hex:Nup153
P6, 4U0D: Hex:Nup153 P212121, 4U0E: Hex:PF74 P6, 4U0F:
Hex:BI-2 P6.
Supporting Information
Figure S1 Superposition of hexamer:ligand complexed
structures obtained in different spacegroups. In each case
the P6 and P212121 hexamer structures in complex with either
NUP153 or CPSF6 have been superposed. The P6 structures are
shown in gray and P212121 in yellow. A close-up view of the
binding site is shown, comprising two adjacent monomers. The
capsid is depicted in a secondary structure representation whilst
the ligands are shown in stick form.
(PDF)
Figure S2 Binding of HIV-1 hexamer to CPSF6 and
NUP153 mutant peptides by ITC. ITC isotherms are shown
for the named titrants. The concentration of each titrant is also
given. Approximate affinities are shown for interactions where a
binding isotherm could be fitted. NB = no binding detectable.
(PDF)
Figure S3 Water-mediated interactions between
NUP153 peptide and HIV-1 hexamer. A close-up view of
the binding site in the P6 complexed structure between HIV-1
hexamer and NUP153 peptide is shown. Parts of two adjacent
capsid monomers are shown in gray and teal. NUP153 is shown in
pink in a stick representation. Water molecules are indicates as
blue spheres and are numbered according to the deposited crystal
structure. Important hexamer and peptide residues are labelled,
with peptide labels in italic.
(PDF)
Figure S4 Superposition of PF74 and BI-2 on the
uncomplexed P212121 hexamer structure (pdb 3H4E).
The ‘open’ and ‘closed’ states adopted in 3H4E as shown in
Figure 3B, superposed onto the orthorhombic hexamer structures
of PF74 and BI-2. A close-up view of the binding site is shown in
which one monomer is in gray, while the ‘open’ and ‘closed’ states
of the second monomer in 3H4E are shown in teal and light green
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respectively. PF74 from the superposed complexed structure is
shown in green (left) whilst BI-2 is shown in orange (right). As can
be seen, PF74, but not BI-2, clashes with the ‘closed’ conformation.
(PDF)
Figure S5 Reversibility and kinetics of PF74 inhibition.
(A) Time-of-addition experiment in which PF74 was added to
HeLa cells at either low (1 mM) or high (30 mM) doses at different
times post-infection with VSV-G pseudotyped GFP-encoding
HIV-1 vector. Infectivity was then determined after 48 hours
and normalized to cells treated with DMSO. (B & C) PF74 was
added coincident with infection or 2 hours post-infection. Cells
were transferred into media with (wash) or without (washout) PF74
after 4 hours of drug treatment. Reverse transcription was
determined after 4 hours of recovery (B), while infection levels
were determined after 48 hours (C).
(PDF)
Text S1 Chemical synthesis of PF74 derivatives. Syn-
thetic schemes are provided for PF74 compounds. Data from mass
spectra (ESI-MS) and NMR spectra are given for each compound.
(DOCX)
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